Computational study of some cancer drugs as potent inhibitors of GSK3β

A series of known Food and Drug Administration (FDA) approved anticancer drugs were collected from the literature and docked against Glycogen synthase kinase 3β (GSKβ) receptor which has been identified in present time as a target for therapeutic anticancer agents. The compounds binding affinities (free energy of binding) were calculated after the chemical structures of the ligands were optimized and energy minimised within the binding pockets’ of the receptor GSKβ, which hasthe protein data bank identification of 3L1S presented in the work. SB 415286 was identified as the best drug for inhibiting 3L1S, its binding energy was reported as -37.288 kcal, but its significant hydrogen bond contribution given as -7.269 kcal which eclipsed all other calculated for this study, was notable. The nature of this interaction was further explored by correlating the binding affinities of the compounds with their molecular descriptors and developing realistic mathematical models using both linear and non linear regression techniques.

Abstract licence: CC BY-NC-ND

1. 2.

   Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response. · 2012

2. 4.

   Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance · 2012

3. 6.

   GSK-3 as potential target for therapeutic intervention in cancer · 2014

4. 20.

   Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention · 2014

5. 31.

   Targeting GSK3 and Associated Signaling Pathways Involved in Cancer · 2020

31 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.